Inclusion Criteria:

- Histologically or cytologically documented advanced epithelial ovarian cancer
measurable with CT and/or MRI

- Received prior chemotherapy regimen(s) for ovarian cancer, at least one being a
platinum based therapy (PBT)

- Evidence of platinum resistant or refractory disease

- ECOG Performance Status 0 - 1

- Life expectancy > 3 months

- Signed informed consent (IC)

- Women of child-bearing potential must have a negative serum or urine pregnancy test.
Nursing patients are excluded.

- Women of child-bearing potential must not become pregnant while participating in the
study

- Adequate haematological and biological functions

Exclusion Criteria:

- Patients with mixed mullerian tumours (MMT) (carcinosarcomas)

- Known brain metastases

- Another known active cancer within the last 5 years

- Radiotherapy to more than 30 % of bone marrow

- Participation in another therapeutic clinical study within 30 days of enrolment or
during this clinical study

- Concomitant treatment with a non-permitted medication

- A history of allergic reactions or sensitivity attributed to compounds of similar or
biological composition to CP-4055, i.e., ara-C and/or egg

- Any serious concomitant systemic disorders incompatible with the clinical study

- Any significant CNS or psychiatric disorder(s) that would hamper the patient's
compliance

- Pregnancy or breastfeeding

- Known positive status for HIV and/or hepatitis B or C

- Drug and/or alcohol abuse

- Any reason why, in the investigator's opinion, the patient should not participate